Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden
· Delayed Price · Currency is SEK 1.058
+0.038 (3.73%)
Apr 29, 2026, 11:17 AM CET
Diamyd Medical AB Revenue
Diamyd Medical AB had revenue of 99.00K SEK in the quarter ending February 28, 2026, with 15.12% growth. This brings the company's revenue in the last twelve months to 362.00K, up 98.90% year-over-year. In the fiscal year ending August 31, 2025, Diamyd Medical AB had annual revenue of 130.00K.
Revenue (ttm)
362.00K
Revenue Growth
+98.90%
P/S Ratio
436.70
Revenue / Employee
8.83K
Employees
41
Market Cap
158.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 130.00K | - | - |
| Aug 31, 2024 | 130.00K | -416.00K | -76.19% |
| Aug 31, 2023 | 546.00K | 92.00K | 20.26% |
| Aug 31, 2022 | 454.00K | 201.00K | 79.45% |
| Aug 31, 2021 | 253.00K | -88.00K | -25.81% |
| Aug 31, 2020 | Pro | Pro | Pro |
| Aug 31, 2019 | Pro | Pro | Pro |
| Aug 31, 2018 | Pro | Pro | Pro |
| Aug 31, 2017 | Pro | Pro | Pro |
| Aug 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elicera Therapeutics AB | 10.64M |
| Alligator Bioscience AB | 839.00K |
| Xbrane Biopharma AB | 152.35M |
| NextCell Pharma AB | 9.83M |
| IRLAB Therapeutics AB | 57.46M |
| Xintela AB | 2.28M |